Optimizing drug combinations for recurrent high grade astrocytic glioma using patient-derived organoids

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study focuses on evaluating the feasibility of the Quadratic Phenotypic Optimization Platform (QPOP) in treating recurrent high grade astrocytic glioma. Brain tumor samples will be collected from patients to generate patient-derived organoids (PDOs), which will then undergo drug screening to identify optimal drug combinations. The study aims to establish organoid models that reflect the biological characteristics of gliomas and assess their therapeutic responses to various drug combinations. Additionally, non-invasive imaging tools will be utilized to monitor treatment effects and correlate them with clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Pre-screening:

1. Patients 21 years of age or older, with ECOG performance status 0 to 2, and with a life expectancy of more than 3 months with suspected high grade astrocytic glioma, fit for treatment comprising standard-of-care therapy with adjuvant temozolomide and radiotherapy if the diagnosis of high grade astrocytoma is pathologically confirmed.
2. Signed informed consent obtained before any study specific procedure. Subjects must be able to understand and be willing to sign the written informed consent.

   * Patients will be enrolled at the time of initial surgery but study imaging and further PDO generation will not take place if the patient is subsequently found not to meet the histological criteria or will not be receiving standard adjuvant temozolomide/ radiotherapy.

All subsequent criteria apply to the main study only:

1. Patients 21 years of age or older, with ECOG performance status 0 to 2, and life expectancy of more than 3 months with pathologically confirmed high grade astrocytic glioma, having undergone first-line standard-of-care therapy with surgery/biopsy followed by temozolomide and radiotherapy. Subjects with truncated adjuvant chemoradiotherapy may be enrolled at the Principal Investigator's discretion.
2. Documented tumor progression based on standard clinical, radiological or histological criteria, and deemed suitable for second line systemic therapy.
3. Sufficient tumor tissue available for PDO generation at baseline and at least one available or pending QPOP result.
4. Adequate organ function as defined by:

1\. Bone marrow function i. Haemoglobin ≥ 9g/dl ii. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L iii. Platelet count ≥ 100 x 109/L. 2. Liver function i. Bilirubin \< 2.5x upper limit of normal (ULN) ii. Alanine transaminase (ALT) and aspartate transaminase (AST) \< 2.5x ULN or \< 5x ULN if liver metastases are present iii. Prothrombin time (PT) within the normal range for the institution. 3. Renal function i. Plasma creatinine \<1.5x institutional ULN 5) Capable of swallowing tablets. 6) Recovery from any previous drug- or procedure-related toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 Grade 0 or 1 (except alopecia), or to baseline preceding the prior treatment.

Exclusion Criteria (both pre-screening/ main study)

1. Chemotherapy, radiotherapy, surgery, immunotherapy or other therapy within 2 weeks of study entry.
2. Pregnancy or breastfeeding at the point where systemic anti-cancer therapy is initiated. Women of childbearing potential must have a negative pregnancy test at the point where systemic anti-cancer therapy is initiated. Women of childbearing potential and men, must agree to use adequate contraception (barrier method of birth control) while on anti-cancer treatment and until at least 3 months after the last study drug administration.
3. Concurrent cancer which is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumours (Ta, Tis \& T1) or any cancer curatively treated less than 5 years prior to study entry.
4. Patients with leptomeningeal dissemination of disease and/or pure spinal high grade gliomas will be excluded.
5. Kidney disease which would clinically disqualify the subject from serial MRI scans with gadolinium contrast.

Where it's running

• Department of Hematology-Oncology, National University Hospital
  Singapore, Singapore Recruiting
• Ng Teng Fong General Hospital
  Singapore, Singapore Not yet recruiting

Study contacts

• Principal investigator: Andrea Wong — National University Hospital, Singapore
• Study coordinator: Andrea Wong
• Email: andrea_la_wong@nuhs.edu.sg
• Phone: +65 6908 2222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using special MRI to detect inflammation in brain tumors

  This study is testing a special MRI technique that uses a contrast agent to see if it can help doctors spot inflammation in brain tumors like vestibular schwannomas and gliomas.

  Recruiting Northern Care Alliance NHS Foundation Trust · Salford, Greater Manchester · NCT06572475

• Precision brain mapping to guide neuromodulation after spontaneous intracerebral hemorrhage

  This trial tests whether personalized transcranial magnetic stimulation targets, identified with individual brain maps, help improve motor and cognitive functions after spontaneous ICH.

  Recruiting at 2 sites National University Hospital, Singapore · Singapore and 1 other locations · NCT07908264

• Multimodal Prehabilitation for Gastric Cancer Patients

  This program tests whether a combined pre- and post-operative wellness plan can reduce inflammation after gastric cancer surgery in adults.

  Recruiting National University Hospital, Singapore · Singapore · NCT07839702

• Different ways to use non-invasive brain stimulation to help stroke recovery

  This study tests if different non-invasive brain stimulation methods can improve motor and language recovery for stroke patients, depending on their goals and medical history.

  Recruiting at 2 sites National University Hospital, Singapore · Singapore and 1 other locations · NCT07786649

• Mepitel Film for Preventing Radiation Dermatitis in Breast Cancer Patients in Singapore

  This observational study tests whether Mepitel Film can help prevent radiation dermatitis in breast cancer patients getting whole breast or chest wall radiotherapy in Singapore.

  Recruiting National University Hospital, Singapore · Singapore · NCT07729423

• Comparing Acute Medical Unit care versus usual ward care for adults with sudden medical illnesses

  This research will see if care in an Acute Medical Unit (AMU) leads to better outcomes than usual general-ward care for adults admitted from the emergency department with infections, falls, or COPD flare-ups.

  Recruiting National University Hospital, Singapore · Singapore · NCT07536035

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.